Quick Answer
Lexeo Therapeutics, Inc. reported Net Income of -$99.96 million for fiscal year 2025.
Lexeo Therapeutics, Inc. Net Income — Annual History
| Fiscal Year | Net Income | YoY Change |
|---|---|---|
| 2025 | -$99.96M | -1.7% |
| 2024 | -$98.33M | -48.1% |
| 2023 | -$66.39M | -12.0% |
| 2022 | -$59.28M | — |
Quarterly Net Income
| Quarter Ending | Net Income | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | -$20.28M | +31.2% | +22.3% |
| June 30, 2025 | -$26.10M | -22.9% | +20.1% |
| March 31, 2025 | -$32.66M | -50.6% | -10.7% |
| September 30, 2024 | -$29.49M | -46.7% | -38.9% |
| June 30, 2024 | -$21.24M | -58.0% | +2.0% |
| March 31, 2024 | -$21.68M | -16.2% | -7.8% |
| September 30, 2023 | -$20.11M | -17.9% | -49.6% |
| June 30, 2023 | -$13.44M | +11.2% | +28.0% |
- Lexeo Therapeutics, Inc. showed a decrease of -1.7% in Net Income compared to the prior fiscal year.
- Over the 2022–2025 period, Lexeo Therapeutics, Inc.’s net income has declined by 68.6% (from -$59.28 million to -$99.96 million).
- The most recent figure is from Lexeo Therapeutics, Inc.’s fiscal year 2025 report (Form 10-K), filed with the SEC on March 30, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: